1997). Moreover, our group previously reported that bone metastatic lesions of PCa showed a tendency to change from an osteolytic to an osteogenic pattern, and relapse was often accompanied by an increase in the number of osteolytic lesions in the clinical course (Shimazaki et al. 1992). These findings highlight the significance of OC activity even in osteogenic PCa bone metastases. However, denosumab does not prolong the overall survival of patients with advanced‐stage PCa (Smith et al. 2012). This evidence concerns the gene BGLAP and posterior cortical atrophy.